Advances in Mineral Metabolism (AIMM) annual meetings, 2012-2014

描述（由申请人提供）：矿物质代谢进展（AIMM）是一个年度会议，它结合了基础和临床骨生物学的介绍，提供了广泛的公开讨论机会。AIMM会议已经被广泛的骨生物学家和临床医生所接受，他们连续26年每年聚集在一起，参加体现AIMM精神的骨和矿物质代谢的高质量讨论。AIMM会议的主要目标之一是为年轻科学家提供机会，在一个不令人生畏和互动的场所与更成熟的研究人员密切互动，促进创造性的科学交流。这是通过一些机制来实现的：首先，约翰·哈达德青年研究员获奖者在计划的科学会议上讨论他们的工作；其次，该项目包括开放的基础和临床科学会议，鼓励年轻的研究人员展示最近的发现；第三，每次会议都包括一个长时间的问答环节，年轻研究人员的参与是突出的；第四，教授见面会为小组互动提供了独特的机会，尤其有利于正在接受培训的科学家和年轻的教员。最后，与会者大部分时间都在一起的会议形式，包括长时间的中午休息时间进行非正式讨论，已被证明是增加互动的成功方式。2012年AIMM会议将包括基因组学和表观基因组学会议；炎性骨病的新方法；慢性肾病和骨病；成骨细胞与造血干细胞生态位；生物矿化机制；以及治疗骨质疏松的新生物学方法。一场辩论将讨论钙补充的风险和益处。接下来几年的计划将从2012年会议期间与会者提出的建议清单中选出。这种方法允许与会者参与下一年计划的制定，并确保及时介绍最新的科学发展。本提案要求资金帮助支付会议费用，并支持参加会议的年轻研究人员和初级教师（哈达德奖获得者除外）的注册和旅行费用。我们为2012年、2013年和2014年AIMM年会申请资金，这些年会都将在斯诺马斯会议中心举行。美国国立卫生研究院的支持将大大有助于AIMM履行其职能，以激发骨骼研究的进一步创造力，并为年轻研究者提供一个论坛，以促进他们的才能。

DESCRIPTION (provided by applicant): Advances in Mineral Metabolism (AIMM) is an annual meeting which combines presentations on basic and clinical bone biology in a format that provides extensive opportunity for open discussion. The AIMM meeting has been embraced by a broad spectrum of bone biologists and clinicians who have gathered annually for 26 consecutive years to participate in the high quality discussions of bone and mineral metabolism which embody the spirit of AIMM. One of the major goals of the AIMM meeting is to provide opportunities for young scientists to interact closely with more established researchers in a non-intimidating and interactive venue that fosters creative scientific exchange. This is accomplished through a number of mechanisms: first, the John Haddad Young Investigator awardees discuss their work within the planned scientific sessions; second, the program includes open basic and clinical science sessions in which young investigators are encouraged to present recent findings; third, each session includes a lengthy question-answer period where participation of young investigators is prominent; fourth, the meet-the-professor sessions provide unique opportunities for small-group interaction that particularly benefit scientists-in-training and youn faculty. Finally, the format of the meeting where attendees are together most of the time and that includes a long midday break for informal discussions has been shown to be a successful way to increase interaction. The 2012 AIMM meeting will include sessions on genomics and epigenomics; new approaches to inflammatory bone disease; Chronic Kidney Disease and bone disease; osteoblasts and the hematopoietic stem cell niche; mechanisms of biomineralization; and novel biological approaches for osteoporosis. A debate will address the risks and benefits of calcium supplementation. The program for the following years will be selected from a list of suggestions made by the participants during the 2012 meeting. This method allows participation of the attendees in the development of the following year's program, and it insures that recent scientific developments will be presented in a timely fashion. This proposal requests funds to help defray the costs of the meeting and support registration and travel costs for young investigators and junior faculty (other than Haddad awardees) that attend the meeting. We request funds for the 2012, 2013, and 2014 AIMM annual meetings, which will all take place at the Snowmass Conference Center. NIH support will significantly contribute to allow AIMM to fulfill its function to stimulate further creativity in bone research and to provide young investigators with a tribune to promote their talent. PUBLIC HEALTH RELEVANCE: Advances in Mineral Metabolism (AIMM) was established as a meeting to present state-of- the-art basic and clinical bone biology in a forum that would be collegial and non-intimidating for young investigators and scientists-in-training. The success of the meeting has endured for 26 consecutive years and many important advances in the bone field were first discussed at the AIMM meeting. Session at the 2012 AIMM meeting will review the molecular mechanisms of inflammatory bone loss, biomineralization, epigenomics, and present currently available therapeutic approaches for bone disease as well as those that could develop following the characterization of promising targets.